Welcome to our dedicated page for Kairos Pharma, LTD. SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. entered into an Agreement for the Support of Investigator / Institution Initiated Research with Bayer HealthCare Pharmaceuticals Inc. on July 16, 2026. Bayer will provide radium-223 (XOFIGO) for a study evaluating XOFIGO in combination with Kairos’ antibody ENV-105 (carotuximab) in models of prostate cancer bone metastasis.
Kairos is responsible for initiating, managing and financing the study, must obtain Bayer’s prior written approval before making material protocol changes, and will deliver final analysis, interpretation and conclusions to Bayer within 6 months after study completion. A related press release highlights ENV-105 Phase 2 data in resistant metastatic castration-resistant prostate cancer, including an 86% clinical benefit rate and median progression-free survival of more than 13 months, and describes the ENV-105 plus XOFIGO combination as targeting a $570M–$1.3B addressable global market.
Kairos Pharma, Ltd. is reporting interim safety data from an ongoing Phase 1 trial of ENV-105 (carotuximab) combined with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer. Among 13 treated patients, no serious adverse events (Grade 3 or higher) have been observed that are attributed to ENV-105, and all side effects have been manageable with standard supportive care. The study is designed to assess safety, tolerability, and a recommended Phase 2 dose.
ENV-105 is a CD105-targeting antibody intended to overcome resistance to osimertinib, the current gold-standard first-line therapy in EGFR-mutated NSCLC. The company highlights the EGFR-NSCLC market at about $10 billion, growing at a 10.5% CAGR and projected to exceed $13 billion by 2030. ENV-105 is also being evaluated in castrate-resistant prostate cancer, where a Phase 2 trial has shown median progression-free survival exceeding 13 months compared with standard care. The company includes forward-looking statements about the potential of ENV-105 across multiple tumor types.
Kairos Pharma Ltd. reported the results of its 2026 annual stockholder meeting, where 13,450,506 of 21,411,198 eligible common shares were voted, representing 62.81% participation. All four director nominees were elected for one-year terms. Stockholders ratified Weinberg & Company, P.A. as auditor for the year ending December 31, 2026. They also approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1:3 and 1:250, to be implemented at the Board’s discretion. On an advisory basis, stockholders approved executive compensation. In addition, they approved adding 5,000,000 shares to the 2023 Equity Incentive Plan and an evergreen feature allowing a 5% annual share increase for ten years.
Kairos Pharma Ltd. provides a mid-year 2026 update highlighting pipeline expansion and upcoming milestones. The company signed a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for EGFR-mutated lung cancer, part of a treatment landscape valued at $16.2B in 2026. Kairos plans to start a Phase 1 study of CL-741 in EGFR-mutated lung cancer and continue Phase 1 and Phase 2 trials of its lead antibody ENV-105 in non-small cell lung and castrate-resistant prostate cancer. The company notes it is a lean operation with a low monthly burn rate and has secured more than $8 million in non-dilutive funding to support its preclinical and clinical assets.
Kairos Pharma, Ltd. is asking stockholders at its June 29, 2026 virtual annual meeting to elect four directors, ratify Weinberg & Company, P.A. as auditor, and approve several governance items. Proposals include authority for a reverse stock split at a ratio between 1:3 and 1:250 and an advisory vote on executive pay.
The company also seeks approval to add 5,000,000 shares to its 2023 Equity Incentive Plan and adopt an evergreen provision for an automatic 5% annual share increase for ten years. Stockholders of record on May 15, 2026, when 21,411,198 common shares were outstanding, may vote online, by phone, mail, or during the live webcast.
Kairos Pharma, Ltd. furnished an investor presentation in connection with its appearance at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation, available on the company’s website, is intended to update investors on its clinical program and partnering activities.
The materials are furnished, not filed, under Item 8.01 of the Exchange Act and attached as Exhibit 99.1, meaning they are not subject to Section 18 liability or automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. reports Q1 2026 results with a net loss of $1,654 thousand, wider than $1,262 thousand a year earlier, and no revenue. Operating expenses rose to $1,690 thousand, driven by higher research and development and public-company costs.
Cash and cash equivalents were $3,675 thousand at March 31, 2026, down from $4,491 thousand at year-end 2025. The company raised gross proceeds of $385 thousand (net $367 thousand) via an At the Market equity program and has an Equity Line of Credit and a $75,000 thousand shelf registration available.
The filing states that recurring losses, cash used in operations of $1,036 thousand in the quarter, and limited cash raise substantial doubt about Kairos’s ability to continue as a going concern. The company is committing to additional manufacturing and development agreements for its ENV-105 program and has signed a binding term sheet to acquire CL-273 in exchange for equity and future milestones, increasing its need for external financing.
Kairos Pharma, Ltd. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 29, 2026. Stockholders of record as of May 15, 2026 may vote; there were 21,411,198 shares outstanding on the Record Date. The Board asks shareholders to vote on four routine governance items plus two material proposals: (1) election of four directors and (2) ratification of auditors; (3) approval of a reverse stock split authorizing the Board to combine shares at a ratio between 1:3 and 1:250; and (4) advisory approval of executive compensation. The Board also seeks approval to increase the 2023 Equity Incentive Plan by 5,000,000 shares and to add an evergreen provision granting an automatic 5% annual increase for ten years. The proxy materials and the annual report are available at kairospharma.com and via proxyvote.com.
Kairos Pharma, Ltd. is registering 6,425,000 shares of common stock for resale pursuant to a prospectus supplement dated April 1, 2026. The registration covers 2,500,000 shares underlying pre-funded warrants (exercise price $0.001), 3,750,000 shares underlying common warrants (exercise price $1.40), and 175,000 shares underlying placement-agent warrants (exercise price $1.40).
This supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed March 31, 2026) and updates the Prior Prospectus dated February 4, 2025. Shares underlying the warrants were issued in a private placement that closed January 16, 2025. Shares outstanding were 21,411,198 as of March 31, 2026.